Ainos, Inc. (AIMD) AI Stock Analysis
AIMD AI stock analysis summary
AI ResearchAinos, Inc. is a healthcare innovator and medical technology company specializing in point-of-care testing and novel therapeutics. The company generated $13,600 in trailing twelve month revenue with an operating margin of -2894135.5%, reflecting substantial operating losses. Its shares have declined 77.1% over the past year while holding $1.4M in cash and short-term investments against $13.8M in total debt.
- Market cap
- $6.8M
- Revenue (TTM)
- $13,600
- P/E
- — fwd 13.9x
- 1Y return
- -77.1% S&P 500 16.8%
- Avg. target
- —
Bull case
- Ainos achieved a 5-year revenue compound annual growth rate of 49.6% from FY2020 to FY2025.
- The forward price-to-earnings ratio is 13.9x, which is lower than the peer group median of 18.8x for its US-listed Technology peers.
- Inside ownership remains high at 70.9%, aligning leadership stakes with company equity.
Bear case
- Trailing twelve month revenue stands at just $13,600, accompanied by an operating margin of -2894135.5%.
- Net debt reached $12.4M against a cash position of only $1.4M as of June 30, 2026.
- The stock has fallen 77.1% over the past 12 months, trailing the S&P 500 return of 16.8%.
What Ainos does
Ainos, Inc. develops medical technologies focused on point-of-care testing and medical treatments across multiple disease indications. Its product portfolio features a COVID-19 antigen rapid test kit, a cloud-based test management application, COVID-19 nucleic acid tests, and point-of-care diagnostic tests for volatile organic compounds. The company is also developing Very Low-Dose Oral Interferon Alpha for broad therapeutic applications. Additionally, Ainos advances Synthetic RNA technology via its SRNA platform to contribute to molecular diagnostics and therapeutic development.
Growth and profitability
Revenue has shown significant volatility, rising from $594,563 in FY2021 to $3.5M in FY2022, before falling 96.5% to $122,112 in FY2023. Revenue dropped 83.0% to $20,729 in FY2024, then rebounded 499.0% to $124,157 in FY2025. Net income has stayed deeply negative, recording -$3.9M in FY2021, -$14.0M in FY2022, -$13.8M in FY2023, -$14.9M in FY2024, and -$14.8M in FY2025. Gross margin was -3767.2% in FY2025, alongside an operating margin of -11268.3%. For the latest quarter ended June 30, 2026, quarterly revenue fell 96.7% year-over-year, bringing trailing twelve month revenue to $13,600 with an operating margin of -2894135.5% and diluted earnings per share of -$2.54.
Balance sheet and cash flow
As of the quarter ended June 30, 2026, Ainos held $1.4M in cash and short-term investments compared to $13.8M in total debt, yielding net debt of $12.4M. Shareholders' equity was $3.3M against total assets of $19.6M. Liquidity indicators show a current ratio of 0.13 and a debt-to-equity ratio of 4.21. Operating cash flow stood at -$4.6M and free cash flow was -$4.6M in FY2025. During FY2025, capital expenditures were $34,561 and share buybacks totaled $260.
Valuation and performance
Ainos carries a market capitalization of $6.8M and an enterprise value of $22.7M. Its price-to-sales multiple is 501.6x, considerably above the 2.8x median of its US-listed Technology peers. The company has a forward P/E of 13.9x and a price-to-book ratio of 3.1x, compared to a forward P/E median of 18.8x for its peer group. The PEG ratio sits at 0.93. Over the past year, AIMD stock fell 77.1%, while the S&P 500 returned 16.8%. Over five years, the stock has dropped 99.7%, trailing the S&P 500 return of 83.0%.
What analysts expect
The company has an earnings track record showing 0 EPS beats over the last 4 quarters. No consensus analyst price targets, recommendations, or forward EPS estimate figures are provided. The company's next earnings report date is scheduled for November 12, 2026. Trading at $0.92 as of October 16, 2026, the stock has traded between a 52-week low of $0.87 and a 52-week high of $4.03, sitting 43.8% below its 200-day moving average.
Key risks and what to watch
- Liquidity risk is elevated given a current ratio of 0.13 and total debt of $13.8M as of June 30, 2026.
- Operating cash burn continued with negative free cash flow of -$4.6M in FY2025 against $1.4M in cash reserves.
- Quarterly revenue fell 96.7% year-over-year in the quarter ended June 30, 2026, reflecting extreme commercial volatility.
- The company recorded 0 EPS beats across the last 4 quarters, highlighting consistent difficulty meeting earnings expectations.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this AIMD AI stock analysis
This page is an AI-written research summary of Ainos, Inc. (AIMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: AIMD income statement, AIMD balance sheet, AIMD key metrics, AIMD chart. See the AIMD stock overview for the latest quote and news.
AIMD AI stock analysis FAQ
What does Ainos, Inc. do?
Ainos, Inc. is a medical technology company developing point-of-care diagnostics, such as COVID-19 antigen tests and volatile organic compound tests, as well as therapeutics including Very Low-Dose Oral Interferon Alpha and Synthetic RNA platforms.
What is Ainos' current debt and cash position?
As of June 30, 2026, Ainos held $1.4M in cash and short-term investments alongside $13.8M in total debt, resulting in net debt of $12.4M and a current ratio of 0.13.
How has AIMD stock performed relative to the broader market?
Over the past year, AIMD stock declined 77.1% compared to a 16.8% gain for the S&P 500. Over five years, the stock has fallen 99.7% while the S&P 500 gained 83.0%.
When is Ainos reporting its next quarterly earnings?
Ainos has its next earnings date scheduled for November 12, 2026.
Does Ainos pay a dividend?
No, Ainos does not pay a dividend.